UBS AM’s Anika Therapeutics ANIK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.82K Buy
+296
New +$5.67K ﹤0.01% 3893
2022
Q4
– Sell
-8,829
Closed -$210K – 2562
2022
Q3
$210K Sell
8,829
-1,580
-15% -$36.4K ﹤0.01% 2594
2022
Q2
$232K Sell
10,409
-8,829
-46% -$197K ﹤0.01% 2543
2022
Q1
$483K Hold
19,238
– – ﹤0.01% 2476
2021
Q4
$689K Hold
19,238
– – ﹤0.01% 2405
2021
Q3
$819K Buy
19,238
+3,253
+20% +$134K ﹤0.01% 2269
2021
Q2
$692K Sell
15,985
-558
-3% -$23.8K ﹤0.01% 2402
2021
Q1
$675K Hold
16,543
– – ﹤0.01% 2273
2020
Q4
$749K Hold
16,543
– – ﹤0.01% 2126
2020
Q3
$585K Buy
16,543
+7,714
+87% +$279K ﹤0.01% 2067
2020
Q2
$333K Sell
8,829
-6,955
-44% -$229K ﹤0.01% 2254
2020
Q1
$456K Sell
15,784
-682
-4% -$27.6K ﹤0.01% 2008
2019
Q4
$854K Buy
16,466
+633
+4% +$36.8K ﹤0.01% 1993
2019
Q3
$869K Buy
15,833
+9,198
+139% +$472K ﹤0.01% 2022
2019
Q2
$270K Buy
+6,635
New +$242K ﹤0.01% 2443
2018
Q2
– Sell
-33
Closed -$1.64K – 2783
2018
Q1
$1.64K Hold
33
– – ﹤0.01% 2636
2017
Q4
$1.78K Hold
33
– – ﹤0.01% 2555
2017
Q3
$1.91K Hold
33
– – ﹤0.01% 2506
2017
Q2
$1.63K Buy
+33
New +$1.52K ﹤0.01% 2491
2016
Q4
– Sell
-5,500
Closed -$263K – 2502
2016
Q3
$263K Hold
5,500
– – ﹤0.01% 2333
2016
Q2
$295K Hold
5,500
– – ﹤0.01% 2229
2016
Q1
$246K Hold
5,500
– – ﹤0.01% 2317
2015
Q4
$210K Buy
+5,500
New +$210K ﹤0.01% 2509
2015
Q2
– Sell
-5,200
Closed -$214K – 2697
2015
Q1
$214K Buy
+5,200
New +$210K ﹤0.01% 2455
2014
Q3
– Sell
-4,800
Closed -$222K – 2561
2014
Q2
$222K Buy
+4,800
New +$213K ﹤0.01% 2358

Other funds holding ANIK

UBS AM's ANIK Position: Q3 2026 in Review

UBS AM opened a new position in Anika Therapeutics (ANIK) in Q3 2026: 296 shares worth $5.82K. The stake represents ﹤0.01% of the portfolio and ranks #3893 among its holdings. This is a return to the name: UBS AM previously reported a position in ANIK as recently as Q3 2022.

UBS AM first reported a position in ANIK in Q2 2014 and has held it in 25 quarters since. The position peaked at $869K in Q3 2019. 122 funds tracked by Wall St. Rank hold ANIK as of Q3 2026.

  • UBS AM held 296 shares of Anika Therapeutics worth $5.82K as of Q3 2026.
  • Anika Therapeutics was a new UBS AM position in Q3 2026.
  • Anika Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #3893 holding.
  • UBS AM first reported a position in Anika Therapeutics in Q2 2014 and has held it in 25 quarters since.
  • UBS AM's Anika Therapeutics position peaked at $869K in Q3 2019.
  • 122 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2026.

Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.